WASHINGTON, DC -- Data from a phase 3b study demonstrates that adults with attention deficit hyperactivity disorder (ADHD) who received once daily lisdexamfetamine (Vyvanse) demonstrated significant improvements in attention throughout the day. The drug’s manufacturer noted that the study, which was published in the journal Behavioral and Brain Functions, marks the first time that an oral long-acting stimulant medication for ADHD has proved effective 14 hours post dose.
